0102030405
I-GMP-TL101 Anti-Human CD3 mAb Antigen ukuqatshelwa, ukuhanjiswa komqondiso kunye nokusebenza kweeseli ze-T
Product Overview
I-Anti-Human CD3 mAb (GMP TL101) yenzelwe ukuququzelela ukuqatshelwa kwe-antigen, ukuhanjiswa komqondiso, kunye nokusebenza kweeseli ze-T. Le antibody ye-monoclonal yinxalenye ebalulekileyo yophando kunye nezicelo zeklinikhi ezibandakanya ukuguqulwa kweeseli ze-T.
Ezona mpawu
● Ukuguqulwa koMqondiso: Ukulungelelanisa ngokufanelekileyo ukuqaphela i-antigen kunye nokuhanjiswa kwesignali, okubalulekileyo ekusebenzeni kwe-T cell.
● Ukwenziwa kwe-GMP: Iveliswe phantsi kweemeko ezingqongqo ze-GMP ukuqinisekisa umgangatho wemveliso kunye nokuveliswa kwakhona.
● Ukuchaza ngokuthe ngqo okuPhakamileyo: Imilinganiselo ephezulu ye-CD3, iqinisekisa ukujoliswa okuchanekileyo kunye neziphumo ezingephi ekujoliswe kuzo.
● Ukusetyenziswa okubanzi: Kufanelekile kwizicelo ezahlukeneyo, kubandakanywa i-cytometry yokuhamba, inkcubeko yeseli, kunye nophando lonyango.
Usetyenziso
● Uphando lwe-Immunological: Kubalulekile ekufundeni i-T cell receptor (TCR) indlela yokubonisa kunye nokusetyenziswa.
● Uphuhliso loNyango: Uncedo ekuphuhliseni unyango olusekelwe kwi-T cell, kuquka unyango lwe-CAR-T.
● Izifundo zeklinikhi: Zifanele iiprothokholi zophando lweklinikhi ezifuna umgangatho ophezulu, izilwa-buhlungu ezithobela i-GMP.
Iinkcukacha kunye nokuPakisha
● Iinkcukacha:
Ifumaneka ngeesayizi ezininzi ukuze ihambelane neemfuno zovavanyo ezahlukeneyo: 100μg, 500μg, kunye ne-1mg.
Imigangatho yomgangatho ophezulu iqinisekisa ukuhambelana nokuthembeka.
● Ukupakishwa:
Inikezelwe njengolwelo oluyinyumba okanye umgubo we-lyophilized ukuze kube lula ukusetyenziswa kunye nokugcinwa okufanelekileyo.
Ipakishwe ukugcina imfezeko kunye nokusebenza ngexesha lothutho nokuphatha.
Ukugcinwa kunye nokuzinza
Ugcino
Ukusetyenziswa kwexesha elifutshane, gcina kwi-2-8°C.
Ukugcina ixesha elide, gcina ku -20°C ukugcina uzinzo kunye nomsebenzi we-antibody.
Kuphephe ukuphindaphinda imijikelo yokunyibilika komkhenkce ukunqanda ukuthotywa.
Uzinzo
Ugcina uzinzo phantsi kweemeko zokugcina ezicetyiswayo, ukuqinisekisa ukusebenza okuthembekileyo kwizicelo zophando.
Yenzelwe ukuqina, iqinisekisa ukusebenza kwexesha elide.
Imiyalelo yokusetyenziswa
Nciphisa i-antibody kwisithinteli esifanelekileyo okanye esiphakathi phambi kokusetyenziswa.
Lungiselela kwaye usebenzise isisombululo ngokweemfuno zovavanyo lweziphumo ezichanekileyo nezinokuphinda ziphindwe.
Landela iiprothokholi ezifanelekileyo kwisicelo sakho, nokuba yi-flow cytometry, i-immunohistochemistry, okanye uvavanyo olusebenzayo.
Izilumkiso
• Le mveliso yenzelwe kuphela ukusetyenziswa kophando kwaye ayifanelekanga ukuxilongwa kweklinikhi okanye izicelo zonyango.
• Phatha i-antibody ngokwemiyalelo enikiweyo ukugcina umsebenzi wayo kunye nokuthembeka.
• Malunga nayo nayiphi na imiba okanye imibuzo, nceda uqhagamshelane neqela lethu lenkxaso yobugcisa ukuze ufumane uncedo.
• Yandisa uphando lwakho ngee-antibodies zethu eziguquguqukayo nezithembekileyo. Ngolwazi oluneenkcukacha zemveliso kunye nenkxaso, ndwendwela iwebhusayithi yethu.
| Ii-Antibodies ze-Monoclonal | |
| Usetyenziso | Indlela ye-Soluble: i-concentration ye-500 ng / mL iyanconywa, phantsi kweeseli ze-T zinokuthi zisebenze kwaye iiseli ze-CD3⁺CD56⁺T zingandiswa kakhulu. |
| Umsebenzi webhayoloji | Umyinge wokubophelela ngeeseli zeJurkat awuyi kuba ngaphantsi kwe 90% |
| Indlela yokwaleka: | I-10 mL ye-PBS buffer (5μg/mL anti-human CD3) ifakwe kwiflask ye-T75 kwi-4 ° C ngobusuku. Nceda susa i-PBS kwaye uhlambe i-flask nge-saline ngobunono kathathu ngaphambi kokuba uyisebenzise. |
| Endotoxin | |
| Isivakalisi sokuvakalisa | Iiseli ze-CHO |
| Ukuqulunqwa | Inikwe njengesisombululo se-0.22μm esihluziweyo kwi-PBS, PH 7.4 |
| Ukusulungekiswa: | Iprotheyini A ehlanjululwe kwinkcubeko yeseli ephezulu |
| QC Testing Ubunyulu | > 95 % njengoko kumiselwe yiSDS-PAGE |
| Uzinzo kunye noGcino | Iinyanga ezingama-24 ku-2℃ ukuya kwi-8℃. Kuphephe ukuphindaphinda imijikelo yokunyibilika komkhenkce |
| Ubhontsi | Ulwazi lwefayile |
 | GMP-TL101_SDS.pdf |
| GMP-TL101_iPhepha leMveliso.pdf |